@article{5b49fc3e75be43f2853c7e7d576af3d2,
title = "Real-world effectiveness from the asia pacific rim liver consortium for hbv risk score for the prediction of hepatocellular carcinoma in chronic hepatitis b patients treated with oral antiviral therapy",
abstract = "Background. Patients on oral antiviral (OAV) therapy remain at hepatocellular carcinoma (HCC) risk. Risk prediction tools distinguishing treated patients with residual HCC risk are limited. The aim of this study was to develop an accurate, precise, simple-to-use HCC risk score using routine clinical variables among a treated Asian cohort. Methods. Adult Asian chronic hepatitis B (CHB) patients on OAV were recruited from 25 centers in the United States and the Asia-Pacific region. Excluded persons were coinfected with hepatitis C, D, or human immunodeficiency virus, had HCC before or within 1 year of study entry, or their follow-up was <1 year. Patients were randomized to derivation and validation cohorts on a 2:1 ratio. Statistically significant predictors from multivariate modeling formed the Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV (REAL-B) score. Results. A total of 8048 patients were randomized to the derivation (n = 5365) or validation group (n = 2683). The REAL-B model included 7 variables (male gender, age, alcohol use, diabetes, baseline cirrhosis, platelet count, and alpha fetoprotein), and scores were categorized as follows: 0-3 low risk, 4-7 moderate risk, and 8-13 high risk. Area under receiver operating characteristics were >0.80 for HCC risk at 3, 5, and 10 years, and these were significantly higher than other risk models (p <.001). Conclusions. The REAL-B score provides 3 distinct risk categories for HCC development in Asian CHB patients on OAV guiding HCC surveillance strategy.",
author = "Yang, {Hwai I.} and Yeh, {Ming Lun} and Wong, {Grace L.} and Peng, {Cheng Yuan} and Chen, {Chien Hung} and Trinh, {Huy N.} and Cheung, {Ka Shing} and Qing Xie and Su, {Tung Hung} and Ritsuzo Kozuka and Lee, {Dong Hyun} and Eiichi Ogawa and Changqing Zhao and Ning, {Hui Bin} and Rui Huang and Jiayi Li and Zhang, {Jian Q.} and Tatsuya Ide and Huichun Xing and Shinji Iwane and Hirokazu Takahashi and Christopher Wong and Clifford Wong and Lin, {Chia Hsin} and Joseph Hoang and An Le and Linda Henry and Hidenori Toyoda and Yoshiyuki Ueno and Gane, {Edward J.} and Yuichiro Eguchi and Masayuki Kurosaki and Chao Wu and Chenghai Liu and Jia Shang and Norihiro Furusyo and Masaru Enomoto and Kao, {Jia Horng} and Yuen, {Man Fung} and Yu, {Ming Lung} and Nguyen, {Mindie H.}",
note = "Funding Information: Potential conflicts of interest. G. L. W. received research support from AbbVie and Gilead Sciences, served as an advisory board member or consultant for Gilead Sciences, and has been a speaker for Abbott, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, and Otsuka. C.-Y. P. served as an advisory committee member for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Roche. H. N. T. received research support from Gilead, Intercept, and Assembly, served as an advisory board member or consultant with Gilead, and is a speaker with Gilead. R. H. received funding from the National Natural Science Foundation of China (81702011). H. X. received funding from the Beijing Municipal Administration of Hospitals and Clinical Medicine{\textquoteright}s Development of special funding support, code XMLX201837. Ch. W. served as an advisory board member for and owns stocks in Gilead Sciences. Cl. W. served as a speaker for Gilead Sciences. Y. U. received research support from Gilead Sciences, AbbVie, and Bristol-Myers Squibb. E. J. G. received research support from the New Zealand Health Research Council, served as an advisory board member or consultant for Gilead Sciences, Janssen, AbbVie, Arbutus and Roche, served as a speaker for Gilead Sciences and Abbvie, and has other declarations from Nil. Y. E. received research support from Bristol-Myers Squibb and AbbVie, served as an advisory board member or consultant, and served as a speaker for Gilead Sciences. C. W. received support from the National Natural Science Foundation of China (81672025) and the Jiangsu Provincial Medical Innovation Team (CXTDA2017005). N. F. received research support, speaker{\textquoteright}s fees, and honorarium from Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme and also research support from Janssen. J.-H. K. received research support from Bristol-Myers Squibb and Gilead Sciences, served as an advisory board member or consultant for AbbVie, Gilead Sciences, Merck Sharp and Dohme, and PharmaEssentia, and served as a speaker for AbbVie, Ascletis, Bristol-Myers Squibb, Gilead Sciences, and Merck Sharp and Dohme. M.-F. Y. received research support from Bristol-Myers Squibb and Gilead Sciences and served as an advisory board member or consultant for AbbVie, Janssen, Biocartis NV, Bristol-Myers Squibb, Fujirebio Incorporation, Gilead Sciences, Merck Sharp and Dohme, and Sysmex Corporation. M.-L. Yu received research support from Bristol-Myers Squibb, Gilead Sciences, and Merck Sharp and Dohme, served as an advisory board member or consultant for AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck Sharp and Dohme, and served as a speaker for AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck Sharp and Dohme. M. H. N. received research support from Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceutical, B. K. Kee Foundation, and the National Cancer Institute and served as an advisory board member or consultant for Dynavax Laboratories, Gilead Sciences, Intercept Pharmaceuticals, Alnylam Pharmaceuticals, Bristol-Myers Squibb, Novartis, and Janssen Pharmaceuticals. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Publisher Copyright: {\textcopyright} The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/infdis/jiz477",
year = "2020",
doi = "10.1093/INFDIS/JIZ477",
language = "English",
volume = "221",
pages = "389--399",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",
}
